Cancer continues to be a leading cause of disability and early mortality worldwide. Immune checkpoint blockade with PD/L-1 therapies such as Keytruda and Opdivo can induce complete and durable clinical responses in multiple tumors, a breakthrough in cancer treatment over the last decade. However, only around 20% of patients respond and many trials have failed
Many R&D programs in multiple companies are attempting to improve the clinical efficacy of PD/L-1 therapies, but no solution is yet approved. Most of these approaches target T-cells or the tumour microenvironment. Patients with healthier microbiomes respond better and therefore some companies are developing live biotherapeutics to enhance the microbiome, with initially promising clinical data.
Iome-Bio offers a differentiated approach through a targeted mode of action downstream of the microbiome’s action, enabling amplification of the signal with first in class monoclonal antibodies.
Company Details
- Founded
- -
- Address
- 3, Rue De La Porte De L'hôpital, Strasbourg,grand Est 67000,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://iomebio.com/
- Keywords
- MULHOUSE.
- HQ
- Strasbourg, Grand Est
Iome Bio Questions
Iome Bio's website is https://iomebio.com/
Iome Bio's LinkedIn profile is https://fr.linkedin.com/company/iome-bio
Iome Bio's industry is
Biotechnology Research
Iome Bio's top competitors are
Kekkan Biologics,
E4e6 Consulting,
Ilonov,
Mabqi,
Biper Therapeutics,
Roca Therapeutics,
Novalix,
Innate Pharma,
Elikya Therapeutics,
Ksilink.
Iome Bio's categories are Biotechnology Research
Iome Bio's founding year is 2020
